Tenboron appoints Dr. Özlem Ataman to Radiation Oncology Advisor

Dr. Ataman is specialized in clinical radiation related research with technical and in depth understanding of radiation biology and physics as well as clinical endpoints and passionate on improving oncology outcomes. She will play a central role in the team that plans and executes Tenboron’s clinical program.

FIRST PATIENT SUCCESSFULLY DOSED

The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.

TENBORON’S LEAD MOLECULE ENTERS CLINICAL STAGE

The Finnish Medicines Agency Fimea has approved Tenboron’s Phase I clinical trial application.The study will be conducted at the Helsinki University Hospital.Preparations for study initiation are underway.

This website uses cookies to ensure that we give you the best experience on our website.